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ABSTRACT
I ntroduction: We evaluated the efficacy of various strategies utilized for the
control of postoperative pain after minimally invasive hysterectomy. The primary
enhanced recovery after surgery (ERAS) protocol of interest utilized premedication
(acetaminophen, celecoxib and pregabalin), then intraoperative subcutaneous
liposomal bupivacaine followed by scheduled oral acetaminophen and ibuprofen
postoperatively. Patients also had tramadol and oxycodone as needed for moderate or
severe breakthrough pain, respectively.
Materials and Methods: We conducted a retrospective cohort study that included
all patients who underwent minimally invasive hysterectomy (total laparoscopic
hysterectomy and laparoscopic-assisted vaginal hysterectomy) for both benign and
oncologic indications over a two-year period. We then compared six protocols; three
were ERAS protocols and three were traditional pain control methods. The control
group was comprised of the traditional pain control group without intraoperative
placement of local analgesia. Patient medical records were evaluated for
demographics, surgical characteristics, opioid type and dose, pain scores, length of stay
and complications. Opioids were converted to oral morphine dose equivalents.
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Results : 954 patients were included within the six protocols. Median opioid usage was
the lowest in the ERAS group with premedication and highest in the control group
(22.5mg versus 55.0mg, p<0.001). Patients in the ERAS group with premedication, when
compared to control, were three times more likely to decline opioids, (p<0.001) without
any concomitant increase in pain scores.
Discussion: ERAS protocol with premedication was associated with significant reductions
ipostoperative opioid use and median pain scores when compared to traditional
methods.
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INTRODUCTION
Enhanced recovery after surgery (ERAS) programs
have been shown to reduce hospital stay and
decrease cost, opioid use and postoperative
complications without any impact on patient pain
control and satisfaction scores.1-7 ERAS programs
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vary in their specific respective regimens. Generally
they include premedication, early ambulation,
early urinary catheter removal, early feeding, and
multimodal approaches to pain control to minimize
opioid use.1-7 Recently, a randomized control trial
utilizing a combination of liposomal bupivacaine
injected in the subcutaneous space with scheduled
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acetaminophen, and ibuprofen with opioids available
for breakthrough pain reduced day of surgery opioids
by almost 50 percent4, when compared to traditional
methods of pain control. Our subsequent study also
found a 54% reduction in opioids along with a 14%
reduction in pain scores.5 Liposomal bupivacaine is
a lipid encapsulated formulation of bupivacaine that
extends the therapeutic benefit to several days8 and
is indicated for injection into the operative site for
postsurgical pain.8
West Virginia is a high-risk area with 35.2% obesity9
and is one of the highest drug overdose areas in the
country at 41.5 per 100,000 and rising.10 Anecdotally,
the prevalence of opioid abuse and addiction in
the area complicates all aspects of postoperative
pain control. This highlights the importance of
developing new methods of pain control that utilize
a multimodal approach to reduce the need for potent
opioids in this unique population.
Over the past two years, providers at Cabell
Huntington Hospital implemented various
approaches for postoperative pain control. The
implementation and modifications were provider
driven and implemented equally among each
provider’s patients. Each provider utilized the
same protocol for all of their patients, instead of
choosing different protocols for each patient based
on preconceived pain tolerance. Some providers
elected to continue with traditional pain control
methods, while others utilized the traditional
postoperative pain control with the addition of the
On-Q® bupivacaine pump or subcutaneous liposomal
bupivacaine. The On-Q® system utilizes percutaneous
catheters that infiltrate the abdominal and pelvic
cavities with bupivacaine over a two to three day
period. Others utilized ERAS orders with the addition
of liposomal bupivacaine.
Few studies examine the efficacy of multimodal pain
control in benign gynecologic cases. Even fewer
examine this in populations with a high prevalence
of addiction. No existing studies analyze the use of
the local anesthetics, liposomal bupivacaine or OnQ® while comparing their efficacy with traditional
postoperative orders and ERAS. We hypothesized
that a specific ERAS approach that includes
premedication would be superior to traditional
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control methods in controlling postoperative
pain and reducing opioid use. In addition to
premedication, the hypothesized protocol includes
a subcutaneous trocar-site liposomal bupivacaine
injection, scheduled acetaminophen with tramadol
and/or oxycodone as needed for breakthrough pain.
We compared this approach to five other existing
protocols among women undergoing minimally
invasive hysterectomy. Our previously reported
study was a relatively small study with only 100
subjects divided into two groups, multimodal and
traditional methods.5 This study has 954 subjects and
builds on those findings by adding premedication,
evaluation of liposomal bupivacaine and On-Q® with
traditional pain control methods, and analysis of
the potential benefit among patients with benign
pathology.
MATERIALS AND METHODS
This is a retrospective cohort study on women
undergoing minimally invasive hysterectomy
categorized into six existing postoperative
pain management protocols. The protocol of
interest was an enhanced recovery protocol
including premedication, subcutaneous liposomal
bupivacaine, scheduled acetaminophen, and
tramadol and/or oxycodone as needed for
breakthrough pain (ERAS-1). The protocols are
outlined in Table 1. ERAS-2 and 3 are similar,
however they differ from ERAS-1 in that ERAS-2
and 3 do not include premedication. ERAS-2 and
3 differ from each other in that ERAS-3 utilizes
scheduled tramadol rather than as needed tramadol
utilized in ERAS-2. ERAS-3 is the ERAS protocol we
previously reported5. Three other protocols were
considered traditional. Traditional pain control
methods utilize ibuprofen and acetaminophen/
oxycodone for breakthrough pain, with IV morphine
or hydromorphone for severe pain. These protocols
all utilized the same postoperative medication and
only differed in the local that was utilized, liposomal
bupivacaine, On-Q® or none. The group that utilized
traditional postoperative pain medications without
the use of liposomal bupivacaine or On-Q® served as
the control group (SOC).
Patients were included if they underwent minimally
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invasive hysterectomy at Cabell Huntington Hospital,
a tertiary care center, between September 1, 2016
and August 31, 2018 for benign or oncologic
indications. This includes both simple and radical
hysterectomy with or without bilateral salpingooophorectomy. Minimally invasive hysterectomy for
the purposes of this paper include: robotic-assisted
total laparoscopic hysterectomy, total laparoscopic
hysterectomy, and laparoscopic-assisted vaginal
hysterectomy. Patients were excluded if they had
a known intraoperative complication, such as
gastrointestinal injury or genitourinary injury, or
a complication that required reoperation within
twenty four hours. Furthermore, patients were
excluded if an additional abdominal incision was
needed for specimen removal. These exclusions
were necessary to minimize confounding from
pain due to additional incisions, prolonged
catheterization, or bowel repair. Patients were also
excluded if they were discharged on the day of
surgery, due to the inability to track postoperative
pain and opioid use. The Institutional Review Board
approved the study protocol and found it exempt
from full review based on the low risk to the research
subjects. The authors have no financial disclosures.
We have no financial relationship with Pacira
Pharmaceuticals, Inc., the manufacturer of Exparel®
liposomal bupivacaine. Pacira Pharmaceuticals, Inc.
had no role on the study design of this project or in
the analysis of the data.
Patient medical records were evaluated for the
following data points: surgical characteristics,
demographics, type and dose of opioid administered
during hospitalization, and postoperative pain
scores. Operative time was defined as the time
from incision to skin closure as recorded by the
circulating nurse. Pain scores were documented
by the floor nurses every 4 hours as part of their
routine postoperative care using a Likert whole
number scale from 0 to 10 with 0 being no pain
and 10 being severe pain. Our institution defined
adequate pain control as 3 or less. Inadequate pain
control is considered 5 or more. All patients received
the standard prophylactic anti-emetic treatment
which was a scopolamine patch. The need for
breakthrough antiemetic for nausea and vomiting
was also collected.
Preoperative indication was defined as the primary
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indication for the surgery. These indications were
then grouped into indications for oncology, chronic
pelvic pain, abnormal uterine bleeding, and pelvic
organ prolapse. Oncologic indication was defined
as cervical dysplasia or cancer, adnexal mass or
ovarian cancer, endometrial hyperplasia or cancer, or
prophylaxis.
Opioid use recording began once the patient left
the operating suite. Opioids given in the PACU was
defined as the first postoperative hour, regardless of
actual physical location (e.g. recovery room, medical
surgical unit). Opioids given after PACU was defined
as opioids given between postoperative hours 2 and
24. Total opioids was defined as opioids given in the
first 24 hours. Standard opioid dose calculators were
utilized to convert all opioid class medications to oral
morphine equivalents.11,12 Conversion from the given
opioid to oral morphine used the following ratios:
IV morphine 1:3, oxycodone 1:1.5, hydromorphone
1:20, meperidine 1:0.1, hydrocodone 1:1, fentanyl
1:0.3, and tramadol 0:0.1.
For the purposes of this study, opioids given
preoperatively and intraoperatively are not included
in the dose calculation. Primary outcomes were
morphine total equivalents administered during
their postoperative course. Secondary outcomes
include median pain scores, nausea and vomiting.
For equally distributed data with more than two
groups we utilized the analysis of variance (ANOVA)
or analysis of covariance (ANCOVA). For nonparametric data with more than two groups we
utilized the Independent-Kruskal-Wallis tests. MannWhitney U tests was used on non-parametric data
when there were only two groups. Fisher Exact test
was used on all categorical data. All analyses were
performed using SPSS 25.
RESULTS
954 subjects were identified for inclusion within the
six protocols described in Table 1. Demographics of
each groups are shown in Table 2. Mean age ranged
between 44 and 55 years with youngest group as
control group and oldest as the ERAS-2 group (44
years versus 55 years, p<0.001). Mean BMIs were in
the obesity range for each group with the highest
in the ERAS-1 and ERAS-3 groups and the lowest in
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TABLE 1. Groups Included for Analysis
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TABLE 2. Demographics by Group (n=954)

TABLE 3. Primary Outcomes Group (n=954)
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FIGURE 1. Median Opioid Use by Protocol. Median opioid use by group patients who
underwent a hysterectomy for any indication (n=954) in mg PO Morphine.

the control group (36.5 kg/m2 versus 32.1 kg/m2,
p <0.001). ERAS groups had less healthy patients
with higher incidences of hypertension, pulmonary
disease and diabetes. Tobacco use was similar
between the groups. A higher proportion of the
hysterectomies performed in the ERAS groups were
robotic-assisted laparoscopic hysterectomies. ERAS
groups had higher proportion of hysterectomies
performed for oncologic indications whereas
the traditional pain control groups had a higher
proportion of hysterectomies performed for chronic
pelvic pain.
As outlined in Table 3 and Figure 1, patients in the
ERAS-1 group used the least amount of opioids in
the PACU at 0.0mg versus 10.0mg in the control
group (p=0.004). After the PACU, patients in the
ERAS-1 group used 63% less opioids than the control
group (13.8mg versus 37.5mg, p<0.001). Overall
opioid use was the lowest in the ERAS-1 group at
59% less than the control at 22.5mg versus 55.0mg,
(p<0.001). Patients in the ERAS-1 group were three
times more likely, when compared to control, to
decline all opioids after the PACU (OR 3.13, CI 1.367.10, p=0.006). Likewise, patients in the ERAS-1
group were three times more likely, when compared
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to control, to decline all opioids (OR 3.62, CI 1.837.18, p<0.001). When compared to control, ERAS-1
patients were five times more likely to use less than
10mg of opioid (OR 4.93, CI 2.83-8.59, p<0.001). A
higher proportion of the control group used greater
than 50mg and 100mg at 23% (p<0.001) and 9%
(p=0.003) respectively, when compared to the other
groups. Median pain scores were lowest in the
ERAS-2 group at 2.5 and highest in the control group
at 3.5 (p=0.01). ERAS-1 group, when compared to
the control, had a higher proportion of patients
obtaining a pain score of 3 or less, (64% versus 49%,
p=0.01) and 4 or less (87% versus 74%, p=0.002).
Conversely, the control group, when compared
to the ERAS-1 group, had a higher proportion of
patients reporting poorly controlled pain with scores
of 5 or higher (23% versus 10%, p=0.001) and 6 or
higher (9% versus 5%, p=0.019). Patients in the
ERAS-1 group reported the least nausea at 21%
versus 50%, (p<0.001).
For patients undergoing a robotic-assisted
hysterectomy, overall opioid use was lowest in
the ERAS-1 group at 22.5mg versus 58.0mg in the
control group (p<0.001). For patients undergoing a
TLH or LAVH, overall opioid use was likewise lowest

mds.marshall.edu/mjm
© 2022 Marshall Journal of Medicine

Marshall Journal of Medicine
Volume 5 Issue 1

TABLE 4. Primary Outcomes by Group Oncologic Indication (n=413)
Oncological Indication includes: endometrial hyperplasia/malignancy, cervical dysplasia/malignancy, adnexal

FIGURE 2. Median Opioid Use by Protocol by those with Oncologic Indication. Median opioid use by group
in patients who underwent a hysterectomy for oncologic indication (n=413) in mg PO Morphine.
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in the ERAS-1 group at 27.5mg versus 47.5mg in the
control (p=0.045).
Outlined in Table 4 and Figure 2, 413 patients
had a hysterectomy for an oncologic indication.
Patients used similar amount of opioids in the PACU,
regardless of grouping. After the PACU, patients in
the ERAS-1 group used 60% less opioids than the
control group (10.0mg versus 24.8mg, p<0.001).
Overall opioid use was the lowest in the ERAS-2
group at 44% less than the control (22.5mg versus
36.0mg, p<0.001). Patients in the ERAS-1 group
had a higher proportion of patients who declined all
opioids at 11% versus 0% (p=0.006). Median pain
scores were similar amongst the groups. Patients in
the ERAS-1 group reported the least nausea at 17%
versus 25% in the control (p<0.001).
Outlined in Table 5 and Figure 3, 318 patients had a
hysterectomy for chronic pelvic pain. Patients used
similar amount of opioids in the PACU, regardless
of grouping. After the PACU, patients in the ERAS-1
group used 60% less opioids than the control group
(15.0mg versus 37.5mg, p<0.001). Overall opioid
use was the lowest in the ERAS-1 group at 52% less
than the control at 26.3mg versus 55.0mg (p<0.001).
Patients in the ERAS-1 group were six times more
likely, when compared to control, to decline all
opioids after the PACU (OR 6.08, 2.16-17.1, p<0.001).
Likewise, patients in the ERAS-1 group were six times
more likely, when compared to control, to decline
all opioids (OR 6.06, 1.92-19.07, p=0.02). When
compared to control, ERAS-1 patients were ten times
more likely to use less than 10mg of opioid (OR
9.74, 4.00-23.73, p<0.001). Median pain scores were
similar amongst the groups. Patients in the ERAS-2
and ERAS-3 groups reported the least nausea at 31%
versus 54% in the control and 59% in the SOC-OQ
(p<0.001).
DISCUSSION
Our data show that the ERAS-1 protocol was
associated with a dramatic reduction in the overall
opioid use and performed the best in our patient
population, regardless of preoperative indication.
This protocol includes the use of premedication
consisting of acetaminophen, celecoxib, and
pregabalin followed by liposomal bupivacaine
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with scheduled acetaminophen, ibuprofen
and simethicone with as needed tramadol for
breakthrough pain and oxycodone for severe
breakthrough pain. Similar results have been shown
with oncologic patients.2-7 This is the first study to
demonstrate 59% overall reduction in opioid use
when compared to control, in a population that
expects to experience minimal to no pain with
surgery and often demands high potency opioids.
Furthermore, this study is among the first to evaluate
pain control for benign conditions as 57 percent of
cases were for benign indications.
The use of On-Q® without any changes to
postoperative medications did not appear to be
associated with any reduction in postoperative
opioids regardless of the preoperative indication.
The utilization of subcutaneous liposomal
bupivacaine was associated with a 23% reduction
in overall opioid use in patients undergoing a
hysterectomy for any indication. However, there was
no observed difference between those undergoing
a hysterectomy for oncologic indications or chronic
pelvic pain.
ERAS-3, which did not use premedication, was
associated with a 9% reduction in overall opioid
use, which was lower than we previously reported.5
This may be related to a higher n, 190 in our current
study versus 50 in the previous publication. There
was no observed reduction in overall opioid use
in patients undergoing a hysterectomy for chronic
pelvic pain or oncologic indication. We did observe
a similar reduction in pain scores as previously
reported.5
ERAS-1 and ERAS-2 were very similar in structure
with both utilizing liposomal bupivacaine
with scheduled acetaminophen, ibuprofen
and simethicone with as needed tramadol for
breakthrough pain and oxycodone for severe
breakthrough pain. ERAS-1 added premedication
consisting of PO acetaminophen, celecoxib, and
pregabalin. Both ERAS-1 and ERAS-2 showed
significant decreases in overall opioid use of 59 and
55 percent, respectively. ERAS-1 when compared
to ERAS-2 was, however, associated with a higher
proportion of patients declining all opioids after
PACU (25% versus 16%, p<0.001), and declining all
postoperative opioids (16% versus 8%, p<0.001).
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TABLE 5. Primary Outcomes by Group Chronic Pelvic Pain (n=381)

FIGURE 3. Median Opioid Use by Protocol by those with Chronic Pelvic Pain. Median opioid use by group in
patients who underwent a hysterectomy for oncologic indication (n=381) in mg PO Morphine.
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ERAS-1 and ERAS-2 performed similar to each other
for patients undergoing hysterectomy for oncologic
indication with both performing better than the
control. The patients who appear to benefit the most
from the premedication are those undergoing a
hysterectomy for chronic pelvic pain. We observed a
modest decrease of 32% without the premedication
(ERAS-2), when compared to control. However,
the addition of the premedication (ERAS-1) was
associated with a 52% reduction in overall opioid use.
ERAS-1, when compared to ERAS-2, was associated
with a higher proportion of patients declining all
opioids after PACU (31% versus 14%, p<0.001), and
declining all postoperative opioids (25% versus 9%,
p<0.001).
Our data show that opioid use for postoperative pain
can be reduced substantially by using premedication,
a multimodal approach postoperatively and
liposomal bupivacaine. We observed relatively small
or no differences, when compared to the control,
when liposomal bupivacaine or the On-Q® were
used with traditional postoperative medications.
We observed the largest reductions in opioid use
amongst the patients in the enhanced recovery
groups which utilized liposomal bupivacaine
exclusively. This study was not designed to
compare On-Q® with liposomal bupivacaine. It is
unclear if similar reductions would be identified if
the enhanced recovery protocols utilized On-Q®
instead of liposomal bupivacaine. Furthermore, it is
unclear how the enhanced recovery protocols would
perform, if no local anesthetic was utilized.
Strengths of our project include that our study
also explores a unique population that is obese
with a high smoking percentage at 32-41%, and
lives in an area with a high prevalence of opioid
use. Anecdotally, the high prevalence of opioid
use complicates postoperative pain management
as anecdotally we observed that patients expect
to experience little to no pain. This is among the
larger of the studies examining enhanced recovery
in minimally invasive hysterectomy with an n of
954. This is among the first studies to examine pain
control in patients who underwent a hysterectomy
for chronic pelvic pain.
Our study has several limitations. First, as a
retrospective study, patients were not randomized to
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any of the groups. Certain providers implemented
this protocol in all their patients and others
exclusively used traditional approaches. This
does impose a bias in selection and surgical
characteristics, which leads to the aberrations
observed in the intrinsic validity characteristics.
Patients in the control group were younger,
healthier, more likely to undergo hysterectomy for
benign indications, and were less likely to undergo
a robotic-assisted laparoscopic hysterectomy. To
account for this potential confounding, ANCOVA was
utilized to create corrected models shown in Table 6.
These corrected models show similar means when
compared to the uncorrected model. Also shown in
Table 6, model 7 shows the corrected means for each
group, when corrected for age, pathology, estimated
blood loss, preoperative indication, total operative
time, comorbidities and type of hysterectomy. The
corrected model shows a statistically significant
55% reduction in overall opioid use. As noted in
the results section, patients who were in the control
group were more likely to undergo a hysterectomy
for chronic pelvic pain. Model 6 specifically
addresses this by adjusting for preoperative
indication. When adjusted for preoperative
indication, we observed a 57% reduction in opioid
use (28.7mg versus 66.3mg, p<0.001). Therefore,
despite the differences between the groups, it
does not appear that these differences significantly
altered or cofounded our results.
Second, our population is vastly Caucasian, with
insufficient minorities to draw any meaningful
statistical conclusions regarding minorities.
Therefore, this study is not generalizable to minority
populations.
Third, patients who underwent surgery earlier in
the day would logically have a longer postoperative
day 0 and thus use more opioids, however this
discrepancy would have a limited impact as an
additional 4 hours of postoperative time would not
account for the significant differences seen between
the groups. Furthermore, operative start time would
be evenly distributed between the groups as all
providers have their own block time in the morning
for their cases.
Fourth, our study was not designed to evaluate
cost-effectiveness of using liposomal bupivacaine.
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TABLE 6. Unadjusted and Adjusted Total Opioid Mean (mg PO Morphine) By Group (n=954)

Despite the higher initial cost of liposomal
bupivacaine compared to no local anesthetic,6,7
pharmacy costs have been shown to be overall
equivocal6 and overall hospital costs reduced by ten
percent.7
Fifth, a patient’s personal history of drug use was
not included as this information is often inconsistent
and unreliable. Urine drug screens are not routinely
collected preoperatively, therefore this information
was not included. Therefore, our data may not be
reproducible in patients with a known history of
substance dependence. This would be a potential
area for future research.
In conclusion, ERAS-1 is an acceptable alternative
to traditional methods of pain control, regardless of
preoperative indication. This protocol was associated
with the highest opioid use reduction at 59%.
Patients with chronic pelvic pain appeared to benefit
the most and those who received this protocol
were six times more likely to decline all opioids
and ten times more likely to use less than 10mg of
opioid. This study shows the promise of multimodal
protocols in reducing opioid need postoperatively.
Further prospective randomized control trials are
warranted.
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